<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clofarabine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clofarabine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clofarabine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11706" href="/d/html/11706.html" rel="external">see "Clofarabine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12924" href="/d/html/12924.html" rel="external">see "Clofarabine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F152997"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Clolar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866381"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Clolar</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F153014"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite;</li>
<li>
                        Antineoplastic Agent, Antimetabolite (Purine Analog)</li></ul></div>
<div class="block doa drugH1Div" id="F152998"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Calculate BSA prior to each cycle, utilizing actual body weight.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Premedications: </i></b>Clofarabine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]). Consider prophylactic corticosteroids (hydrocortisone 100 mg/m<sup>2</sup> on days 1 to 3) to prevent signs/symptoms of capillary leak syndrome or systemic inflammatory response syndrome (SIRS). Provide supportive care, such as IV fluids and antihyperuricemic treatment, and alkalinize urine (to reduce the risk of tumor lysis syndrome/hyperuricemia).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="325fe1c9-065e-450c-9429-246476af14bd">Acute lymphoblastic leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, relapsed/refractory:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute lymphoblastic leukemia, relapsed/refractory:</b> Adults ≤21 years of age: <b>IV:</b> 52 mg/m<sup>2</sup>/day days 1 through 5; repeat every ~2 to 6 weeks; subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle (subsequent cycles may be administered when ANC ≥750/mm<sup>3</sup>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Off-label dosing:</i> CLOVE regimen: <b>IV:</b> 20 to 30 mg/m<sup>2</sup> once daily on days 1 through 5 (in combination with cyclophosphamide and etoposide) as a bridging regimen to hematopoietic stem cell transplant in patients with relapsed or very high risk disease (Gossai 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute lymphoblastic leukemia, relapsed/refractory (off-label population):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Induction: <b>IV:</b> 40 mg/m<sup>2</sup> once daily for 5 days; may repeat induction cycle once in 3 to 6 weeks if needed (depending on marrow response and recovery) (Kantarjian 2003).</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation:<b> IV:</b> 30 mg/m<sup>2</sup> once daily for 5 days (or last tolerated induction dose, whichever is lower); repeat every 4 weeks for up to a maximum of 6 consolidation cycles (Kantarjian 2003).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="498858a4-7922-47cd-86ca-32108f3e893f">Acute myeloid leukemia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, refractory (off-label use):</b> Adults &lt;70 years of age:</p>
<p style="text-indent:-2em;margin-left:4em;">Induction: <b>IV:</b> 25 mg/m<sup>2</sup>/day for 5 days (in combination with cytarabine and filgrastim) may repeat one time after 21 days if needed (Becker 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Consolidation: <b>IV:</b> 20 mg/m<sup>2</sup>/day for 5 days (in combination with cytarabine and filgrastim) for 1 or 2 cycles (Becker 2011).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990658"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">Clofarabine undergoes renal elimination and exposure is increased as creatinine clearance decreases (Bonate 2011). Minimize the concomitant use of nephrotoxic medications during clofarabine treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Renal impairment at baseline:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 60 mL/minute: Reduce dose to 50% of the usual dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling. Use is not recommended (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis: There are no dosage adjustments provided in the manufacturer's labeling. Use is not recommended (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Renal toxicity during treatment: Serum creatinine increase ≥ grade 3: Discontinue clofarabine; may reinitiate with a 25% dose reduction after patient is stable and organ function recovers to baseline.</p></div>
<div class="block doha drugH1Div" id="F50987876"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment at baseline: There are no dosage adjustments provided in the manufacturer's labeling. Avoid the concomitant use of medications that may cause hepatotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No need for dosage adjustment is expected (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatotoxicity during treatment:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic enzymes and/or bilirubin increase ≥ grade 3: Discontinue clofarabine; may reinitiate with a 25% dose reduction after patient is stable and organ function recovers to baseline.</p></div>
<div class="block doo drugH1Div" id="F20340179"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>: </i>Utilize patient's actual body weight (full weight) for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m2; if a dose reduction is utilized due to toxicity, may consider resumption of full weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society for Blood and Marrow Transplantation practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of BSA in clofarabine dosing for hematopoietic stem cell transplant conditioning regimens (ASBMT [Bubalo 2014]).</p></div>
<div class="block dot drugH1Div" id="F6872379"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematologic toxicity:</b> ANC &lt;500/mm<sup>3</sup> lasting ≥4 weeks: Reduce dose by 25% for next cycle.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonhematologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Clinically significant infection:</i> Withhold clofarabine until infection is under control, then restart at full dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Grade 3 toxicity excluding infection, nausea and vomiting controlled by antiemetics, or transient elevations in transaminases and bilirubin: </i>Withhold clofarabine; may reinitiate with a 25% dose reduction with resolution or return to baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Grade 4 toxicity (noninfectious):</i> Discontinue clofarabine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Capillary leak syndrome or systemic inflammatory response syndrome (SIRS) early signs/symptoms (eg, hypotension, tachycardia, tachypnea, pulmonary edema):</i> Discontinue clofarabine; institute supportive measures. Consider supportive treatment with diuretics, corticosteroids, and/or albumin as clinically appropriate. May consider reinitiating clofarabine with a 25% dose reduction after patient is stable and organ function recovers to baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dermatologic toxicity:</i> Exfoliative or bullous rash, or suspected Stevens-Johnson syndrome or toxic epidermal necrolysis: Discontinue clofarabine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hypotension (during the 5 days of infusion): </i>Discontinue clofarabine. If hypotension is transient and resolves and patient is stabilized, may consider reinitiating with 25% dosage reduction (Clolar Canadian product monograph).</p></div>
<div class="block dop drugH1Div" id="F153007"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12924" href="/d/html/12924.html" rel="external">see "Clofarabine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Consider prophylactic corticosteroids (hydrocortisone 100 mg/m<sup>2</sup> on days 1 to 3) to prevent signs/symptoms of capillary leak syndrome or systemic inflammatory response syndrome (SIRS). Provide IV hydration, antihyperuricemic therapy, and alkalinize the urine to reduce the risk of tumor lysis syndrome/hyperuricemia. Calculate BSA prior to each cycle utilizing actual body weight. Clofarabine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c18f6a0c-02d2-4f2a-9d71-dd967d05c5fe">Acute lymphocytic leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia (ALL), relapsed/refractory: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy:</i> Children and Adolescents: IV infusion: 52 mg/m<sup>2</sup>/day once daily for days 1 to 5 of each cycle; repeat cycle every 2 to 6 weeks following recovery or return to baseline organ function; subsequent cycles should begin no sooner than 14 days from the start of the previous cycle and when ANC ≥750/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i> Limited data available: IV Infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: Dosing regimens variable with very limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-directed dosing: 1.33 mg/kg/day for 5 days in combination with cyclophosphamide and etoposide (O’Connor 2011)</p>
<p style="text-indent:-2em;margin-left:8em;">BSA-directed dosing: 40 mg/m<sup>2</sup>/day for 5 days in combination with cyclophosphamide and etoposide (Inaba 2012); and with topotecan, vinorelbine, thiotepa (TVTC regimen), and dexamethasone in a Phase I trial (Steinherz 2010)</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Usual dose: 40 mg/m<sup>2</sup>/day for 5 days in combination with cyclophosphamide and etoposide has been most frequently studied (Hijiya 2011; Hijiya 2012; Inaba 2012; Locatelli 2009; O’Connor 2011); and with topotecan, vinorelbine, thiotepa (TVTC regimen), and dexamethasone in a Phase I trial (Steinherz 2010). In one trial, the protocol included 5 days of clofarabine therapy during induction and 4 days of therapy for consolidation; this study was also amended to exclude patients with prior hematopoietic stem cell transplantation due to a high incidence of veno-occlusive disease (Hijiya 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f67ba0dd-7fb1-46ed-8cd1-3d903c74c998">Acute myeloid leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia (AML), relapsed/refractory:</b> Limited data available: Children and Adolescents: IV infusion:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Monotherapy:</i> 52 mg/m<sup>2</sup>/day once daily for days 1 to 5 of each cycle; repeat cycle every 2 to 6 weeks for up to 12 cycles following recovery or return to baseline organ function; subsequent cycles should begin no sooner than 14 days from the start of the previous cycle and when ANC ≥750/mm<sup>3</sup>; the trial did not have minimum exclusion age (patient age ≤21 years at time of diagnosis); the youngest patient was 2 years of age (Jeha 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy:</i> 40 mg/m<sup>2</sup>/day once daily for days 1 to 5 of each cycle in combination with cyclophosphamide and etoposide (Inaba 2012)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9438acbe-e23c-4fe9-baa0-396aaeb88ad9">Langerhans cell histiocytosis, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Langerhans cell histiocytosis, refractory:</b> Limited data available: Children and Adolescents: IV: 25 mg/m<sup>2</sup>/day days 1 through 5; repeat every 28 days for 2 to 8 cycles (Simko 2014).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic toxicity: ANC &lt;500/mm<sup>3</sup> lasting ≥4 weeks: Reduce clofarabine dose by 25% for next cycle</p>
<p style="text-indent:-2em;margin-left:4em;">Nonhematologic toxicity:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Clinically significant infection:</i> Withhold treatment until infection is under control, then restart clofarabine at full dose</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 toxicity, excluding infection, nausea, and vomiting, and transient elevations in transaminases and bilirubin:</i> Withhold treatment; may reinitiate clofarabine with a 25% dose reduction with resolution or return to baseline</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade ≥3 increase in creatinine or bilirubin:</i> Discontinue clofarabine; may reinitiate with 25% dosage reduction when creatinine or bilirubin return to baseline and patient is stable; administer antihyperuricemic therapy for elevated uric acid</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 4 toxicity (noninfectious):</i> Discontinue clofarabine treatment</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Capillary leak or systemic inflammatory response syndrome (SIRS) early signs/symptoms (eg, hypotension, tachycardia, tachypnea, pulmonary edema):</i> Discontinue clofarabine; institute supportive measures. May consider reinitiating with a 25% dose-reduction after patient is stable and after organ function recovers to baseline.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dermatologic toxicity:</i> Exfoliative or bullous rash, or suspected Stevens-Johnson syndrome or toxic epidermal necrolysis: Discontinue clofarabine.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Hypotension (during the 5 days of infusion</i>): Discontinue clofarabine. If hypotension is transient and resolves (without pharmacologic intervention), some have suggested that may reinitiate with 25% dosage reduction (Clolar Canadian product monograph).</p></div>
<div class="block dorp drugH1Div" id="F51089942"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: Clofarabine undergoes renal elimination and exposure is increased as creatinine clearance decreases (Bonate 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline renal impairment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;60 mL/minute: No dosage adjustment recommended</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 60 mL/minute: Reduce dose by 50%</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; use with caution (insufficient evidence)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Renal toxicity during therapy:</i> Grade 3 or higher increase in serum creatinine: Discontinue clofarabine; may reinitiate with a 25% dose reduction after patient is stable and organ function recovers to baseline</p></div>
<div class="block dohp drugH1Div" id="F51089943"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline hepatic impairment:</i> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during therapy:</i> Grade 3 or higher increase in bilirubin: Discontinue clofarabine; may reinitiate with a 25% dose reduction after patient is stable and organ function recovers to baseline.</p></div>
<div class="block adr drugH1Div" id="F152970"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in pediatric patients and include off-label use in the treatment of AML.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (12%), flushing (19%), hypertension (13%), hypotension (29%), septic shock (≤17%), tachycardia (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (11%), palmar-plantar erythrodysesthesia (16%), pruritus (43%), skin rash (38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (35%), anorexia (30%), diarrhea (56%; grade 3: 12%), gingival hemorrhage (17%), mucosal swelling (16%), nausea (73%; grades 3/4: 1% to 14%), oral candidiasis (11%), vomiting (78%; grades 3/4: 1% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (83%; grades ≥3: 75%), febrile neutropenia (55%; grades 3/4: 3% to 51%), leukopenia (88%; grades ≥3: 88%), lymphocytopenia (82%; grades ≥3: 82%), neutropenia (10% to 64%; grades ≥3: 3% to 64%), petechia (26%; grade 3: 6%), thrombocytopenia (81%; grades ≥3: 80%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (81%), increased serum aspartate aminotransferase (74%), increased serum bilirubin (45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (83%; including bacterial infection, fungal infection, and viral infection), sepsis (≤17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (21%), chills (34%), fatigue (34%), headache (43%), pain (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (30%), myalgia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (13%), epistaxis (27%), pleural effusion (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (39%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome (4%), pericardial effusion (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (8%), pruritic rash (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Clostridioides difficile colitis (7%), gastroenteritis (adenovirus: &lt;5%), neutropenic typhlitis (&lt;5%), oral mucosal petechiae (5%), pancreatitis (&lt;5%), rectal pain (8%), stomatitis (7%; grade 3: 1%), upper abdominal pain (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Tumor lysis syndrome (6%; grade 3: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic sinusoidal obstruction syndrome (formerly known as hepatic venoocclusive disease: 2%), hyperbilirubinemia (&lt;5%), jaundice (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacteremia (9%), candidiasis (7%), herpes simplex infection (10%), herpes zoster (7%), influenza (&lt;5%), systemic inflammatory response syndrome (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (5%), asthenia (10%), drowsiness (10%), irritability (10%), lethargy (10%), mental status changes (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (9%), back pain (10%), ostealgia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (grades 3/4: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (10%), pulmonary edema (&lt;5%), respiratory distress (10%), respiratory syncytial virus infection (&lt;5%), sinusitis (&lt;5%), tachypnea (9%), upper respiratory tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Enterocolitis (including neutropenic enterocolitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased right ventricular pressure (Jeha 2006), left systolic heart failure (Jeha 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (Jeha 2006), hyponatremia, hypophosphatemia (Jeha 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Major hemorrhage (including cerebral hemorrhage, gastrointestinal hemorrhage, and pulmonary hemorrhage)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatomegaly (Jeha 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug fever (Irie 2022), hallucination (Jeha 2006)</p></div>
<div class="block coi drugH1Div" id="F152983"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer’s US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to clofarabine or any component of the formulation; symptomatic CNS involvement; history of serious heart, liver, kidney, or pancreas disease; severe hepatic impairment (AST and/or ALT &gt;5 x ULN, and/or bilirubin &gt;3 x ULN); severe renal impairment (CrCl &lt;30 mL/minute)</p></div>
<div class="block war drugH1Div" id="F152968"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Dose-dependent, reversible myelosuppression (neutropenia, thrombocytopenia, and anemia) is common; may be severe and prolonged. Patients may be at increased risk for infection due to neutropenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Capillary leak syndrome/systemic inflammatory response syndrome: Clofarabine may cause a cytokine release syndrome (eg, tachypnea, tachycardia, hypotension, pulmonary edema), which may progress to systemic inflammatory response syndrome with capillary leak syndrome and organ dysfunction; may be fatal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Serious and fatal cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Serious and fatal enterocolitis (including neutropenic colitis, cecitis, and <i>C. difficile</i> colitis) has been reported, usually occurring within 30 days of treatment, and when used in combination with other chemotherapy. Enterocolitis may lead to necrosis, perforation, hemorrhage, or sepsis complications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Serious and fatal hemorrhages (including cerebral, GI, and pulmonary hemorrhage) have occurred, usually associated with thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Transaminases and bilirubin may be increased during treatment (including grade 3 and 4 events); severe and fatal hepatitis and hepatic failure have been reported. Transaminase elevations generally occur within 10 days of administration and resolve to ≤ grade 2 within 15 days. The risk for hepatotoxicity, including hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease), is increased in patients who have previously undergone a hematopoietic stem cell transplant.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Clofarabine increases the risk for infections, including opportunistic infection or severe or fatal sepsis. Fungal, bacterial, and viral infections have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Elevated creatinine, acute renal failure, and hematuria were observed in clinical studies. Infection, sepsis, or tumor lysis syndrome may cause an increased risk of renal toxicity in patients receiving clofarabine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome/hyperuricemia: Tumor lysis syndrome may occur as a consequence of leukemia treatment, including treatment with clofarabine, usually occurring in the first treatment cycle. Tumor lysis syndrome may lead to life-threatening acute renal failure; adequate hydration and prophylactic antihyperuricemic therapy will reduce the risk/effects of tumor lysis syndrome.</p></div>
<div class="block foc drugH1Div" id="F152978"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clolar: 1 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (20 mL)</p></div>
<div class="block geq drugH1Div" id="F152966"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323073"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Clofarabine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $48.00 - $176.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Clolar Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $213.87</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866382"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clolar: 1 mg/mL (20 mL)</p></div>
<div class="block adm drugH1Div" id="F152980"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (ASCO [Hesketh 2020]; MASCC/ESMO [Roila 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> Infuse over 2 hours for relapsed/refractory ALL. May be infused over 1 hour for some off-label protocols (Becker 2011; Kantarjian 2003). Continuous IV fluids are encouraged to decrease adverse events and tumor lysis effects. Hypotension may be a sign of capillary leak syndrome or systemic inflammatory response syndrome. Do not administer any other medications through the same intravenous line.</p></div>
<div class="block admp drugH1Div" id="F52612437"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV infusion: Administer by IV infusion over 2 hours per the manufacturer's labeling and in most trials; a few trials have infused over 1 hour (Federl 2005; Jeha 2004; Kantarian 2003). An inline filter is not needed for administration. Do not administer with any other medications through the same intravenous line.</p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (POGO [Dupuis 2011]).</p></div>
<div class="block hazard drugH1Div" id="F49130933"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F152979"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Acute lymphoblastic leukemia, relapsed or refractory:</b> Treatment of relapsed or refractory acute lymphoblastic leukemia in patients 1 to 21 years of age (after at least 2 prior regimens).</p></div>
<div class="block off-label drugH1Div" id="F25722041"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute lymphoblastic leukemia, relapsed or refractory (adults); Acute myeloid leukemia, refractory (patients &lt;70 years of age)</p></div>
<div class="block mst drugH1Div" id="F3401601"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Clofarabine may be confused with cladribine, clevidipine, cytarabine, nelarabine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299065"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3, OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F152972"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OAT1/3 Inhibitors: May increase the serum concentration of Clofarabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OCT2 Inhibitors: May increase the serum concentration of Clofarabine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May increase the serum concentration of OAT1/3 Substrates (Clinically Relevant).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49296749"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who may become pregnant. Patients who may become pregnant should use effective contraception during therapy and for at least 6 months after the last clofarabine dose. Patients with partners who may become pregnant should use effective contraception during therapy and for at least 3 months after the last dose of clofarabine.</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (1-877-635-4499).</p></div>
<div class="block pri drugH1Div" id="F152986"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to clofarabine may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F6871935"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if clofarabine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for at least 2 weeks after the last dose of clofarabine.</p></div>
<div class="block mop drugH1Div" id="F152976"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">CBC with differential and platelets (regularly during treatment); liver and kidney function (during the 5 days of clofarabine administration); coagulation parameters. Monitor BP, cardiac function, and respiratory status during infusion. Monitor for signs and symptoms of tumor lysis syndrome, infection, hepatic sinusoidal obstruction syndrome, dermatologic toxicity, enterocolitis, hemorrhage, cytokine release syndrome (tachypnea, tachycardia, hypotension, pulmonary edema), and capillary leak syndrome/systemic inflammatory response syndrome (rapid onset respiratory distress, hypotension, pleural/pericardial effusion, and multiorgan failure); monitor hydration status.</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F152967"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Clofarabine, a purine (deoxyadenosine) nucleoside analog, is metabolized to clofarabine 5'-triphosphate. Clofarabine 5'-triphosphate decreases cell replication and repair as well as causing cell death. To decrease cell replication and repair, clofarabine 5'-triphosphate competes with deoxyadenosine triphosphate for the enzymes ribonucleotide reductase and DNA polymerase. Cell replication is decreased when clofarabine 5'-triphosphate inhibits ribonucleotide reductase from reacting with deoxyadenosine triphosphate to produce deoxynucleotide triphosphate which is needed for DNA synthesis. Cell replication is also decreased when clofarabine 5'-triphosphate competes with DNA polymerase for incorporation into the DNA chain; when done during the repair process, cell repair is affected. To cause cell death, clofarabine 5'-triphosphate alters the mitochondrial membrane by releasing proteins, an inducing factor and cytochrome C.</p></div>
<div class="block phk drugH1Div" id="F152982"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Decreased with increasing age, based on pharmacokinetic simulations: 5.8 L/kg (3 years old); 3.1 L/kg (30 years old); 2.7 L/kg (82 years old) (Bonate 2011); Children and Adolescents 2 to 19 years: 172 L/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 47%, primarily to albumin </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Intracellulary by deoxycytidine kinase and mono- and diphosphokinases to active metabolite clofarabine 5′-triphosphate; limited hepatic metabolism (0.2%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Children and Adolescents 2 to 19 years: 5.2 hours; Children and Adults: 7 hours; may be prolonged in in the elderly and in patients with renal impairment  (Bonate, 2011)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (49% to 60%, as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51220849"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clofarabine undergoes renal elimination and exposure is increased as creatinine clearance decreases (Bonate 2011). In patients with CrCl 60 to &lt;90 mL/minute, the AUC was increased by 60% and in patients with CrCl 30 to &lt;60 mL/minute, the AUC was increased by 140%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038584"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cistadine | Clobinea | Clofazic | Cloficris | Clolar | Luvuden</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Clofarabin alvogen | Evoltra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Clofazic</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Clofazic | Cloficris | Clolar | Farabine | Hb clovotabin | Metisa | Reluka</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Clofarabin aqvida | Clofarabin ratiopharm | Clofarabin tillomed | Clofarabine tillomed</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Clofazic</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Clofarabin tillomed</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Clofarabina accord | Clofarabina aristo | Clofarabina teva | Clofarabina tillom | Evoltra</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Clofarabine avans | Evoltra</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clofarabine mylan | Clofarabine tillomed | Evoltra | Ivozall</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Clofarabine accord | Clofarabine vivanta | Evoltra</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Farabine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Clofarabina teva | Clofarabina Tillomed | Evoltra</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ivozall</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Clofazic | Clolar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Evoltra | Nuclofar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Clofarabine accord | Clofarabine mylan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clofazic</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Clofarabine norame | Evoltra</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Clolar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clofarabina lkm</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Clofarabine avans | Evoltra</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Evoltra | Klofarabin makpharm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Evoltu | Evorabin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Evoltra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21848522">
<a name="21848522"></a>Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol. 2011;155(2):182-189. doi: 10.1111/j.1365-2141.2011.08831.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/21848522/pubmed" id="21848522" target="_blank">21848522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20582417">
<a name="20582417"></a>Bonate PL, Cunningham CC, Gaynon P, et al, “Population Pharmacokinetics of Clofarabine and its Metabolite 6-Ketoclofarabine in Adult and Pediatric Patients With Cancer,” <i>Cancer Chemother Pharmacol</i>, 2011, 67(4):875-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/20582417/pubmed" id="20582417" target="_blank">20582417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi:10.1016/j.bbmt.2014.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Clolar (clofarabine) [prescribing information]. Cambridge, MA: Genzyme Corporation; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clolar.2">
<a name="Clolar.2"></a>Clolar (clofarabine) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15486072">
<a name="15486072"></a>Faderl S, Gandhi V, O’Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. <i>Blood</i>. 2005; 105:940-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/15486072/pubmed" id="15486072" target="_blank">15486072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24317126">
<a name="24317126"></a>Gossai N, Verneris MR, Karras NA, et al. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). <i>Bone Marrow Transplant</i>. 2014;49(3):440-442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/24317126/pubmed" id="24317126" target="_blank">24317126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354543">
<a name="22354543"></a>Hijiya N, Barry E, Arceci R. Clofarabine in pediatric acute leukemia: current findings and issues. <i>Pediatr Blood Cancer</i>. 2012;59:417-422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/22354543/pubmed" id="22354543" target="_blank">22354543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21967976">
<a name="21967976"></a>Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. <i>Blood</i>. 2001;118 6043-6049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/21967976/pubmed" id="21967976" target="_blank">21967976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883141">
<a name="21883141"></a>Inaba H, Bhojwani D, Pauley JL, et.al. Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. <i>Br J Haematol</i>. 2012;156(2):275-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/21883141/pubmed" id="21883141" target="_blank">21883141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34725963">
<a name="34725963"></a>Irie M, Nakano T, Katayama S, et al. Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis. <i>Cancer Rep (Hoboken)</i>. 2022;5(8):e1579. doi:10.1002/cnr2.1579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/34725963/pubmed" id="34725963" target="_blank">34725963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551141">
<a name="14551141"></a>Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a Novel Nucleoside Analog, is Active in Pediatric Patients With Advanced Leukemia. <i>Blood</i>. 2004;103(3):784-789.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/14551141/pubmed" id="14551141" target="_blank">14551141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16622268">
<a name="16622268"></a>Jeha S, Gaynon PS, Razzouk BI, et al. Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia. <i>J Clin Oncol</i>. 2006;24(12):1917-1923.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/16622268/pubmed" id="16622268" target="_blank">16622268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19652076">
<a name="19652076"></a>Jeha S, Razzouk B, Rytting M, et.al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. <i>J Clin Oncol</i>. 2009;27:4392-4397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/19652076/pubmed" id="19652076" target="_blank">19652076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12791647">
<a name="12791647"></a>Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 Clinical and Pharmacologic Study of Clofarabine in Patients With Refractory or Relapsed Acute Leukemia. <i>Blood</i>. 2003;102(7):2379-2386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/12791647/pubmed" id="12791647" target="_blank">12791647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747360">
<a name="19747360"></a>Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. <i>British Journal of Haematology</i>. 2009;147:371-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/19747360/pubmed" id="19747360" target="_blank">19747360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21689087">
<a name="21689087"></a>O'Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i>. 2011;154:482-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/21689087/pubmed" id="21689087" target="_blank">21689087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24106153">
<a name="24106153"></a>Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. <i>Pediatr Blood Cancer</i>. 2014;61(3):479-487. doi:10.1002/pbc.24772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/24106153/pubmed" id="24106153" target="_blank">24106153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20205253">
<a name="20205253"></a>Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa and vinorelbine for patients with relapsed or refractory leukemia. <i>Pediatr Blood Cancer</i>. 2010;54:687-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clofarabine-drug-information/abstract-text/20205253/pubmed" id="20205253" target="_blank">20205253</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9220 Version 319.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
